"two possibilities: 1) MRK thinks I-vation TA has commercial potential in its own right; or 2) the TA program will remain active only until another embodiment of I-vation is ready to be tested in humans. I lean toward #2."
TA might work well for DME on I-vation (recall the debate about potential benefits of keeping the dose in the low therapeutic range), plus it might be used off label to reduce the frequency of Lucentis injections. I would not discount these possibilities.
Market Data 
Markets 
AI
